Raju Subramanian

Employment

• Amgen Inc
  2005 - Present
• Merck and Co Inc West Point
  1999 - 2005
• Gilead Sciences (United States)

Education

• Stony Brook University Ph. D
  1989 - 1994

Projects & Funding

Projects & funding information is unavailable.

Publications (4)

• Pharmacokinetics and Metabolism of Broad-Spectrum Antivirals Remdesivir and Obeldesivir with a Consideration to Metabolite GS-441524: Same, Similar, or Different?
  Viruses 2025 DOI: 10.3390/v17060836
  +Save
• Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants
  Clinical Pharmacology & Therapeutics 2024 DOI: 10.1002/cpt.3337
  +Save
• Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent
  Molecular Pharmaceutics 2023 DOI: 10.1021/acs.molpharmaceut.3c00626
  +Save
• Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection
  Xenobiotica 2022 DOI: 10.1080/00498254.2022.2159569
  +Save